Plant ID: NPO12477
Plant Latin Name: Dodonaea viscosa
Taxonomy Genus: Dodonaea
Taxonomy Family: Sapindaceae
NCBI TaxonomyDB:
151065
Plant-of-the-World-Online:
30058367-2
Anodyne; Diaphoretic; Febrifuge; Odontalgic; Vulnerary
Brazil; Madagascar; Bangladesh; Sudan; Guinea; Nepal; Bahamas; Rwanda; Tanzania; Peru; Swaziland; Argentina; Cameroon; Cote d'Ivoire; Ecuador; Benin; Ghana; Vietnam; Australia; Iran; Cuba; Venezuela; Zambia; Cape Verde; Papua New Guinea; Malawi; Togo; Trinidad and Tobago; Zimbabwe; China; Vanuatu; Chile; Oman; Dominican Republic; Belize; Sierra Leone; Spain; Nigeria; Liberia; Maldives; Gambia; Philippines; Indonesia; New Caledonia; United States; Sri Lanka; Uruguay; Guinea-Bissau; Kenya; Honduras; New Zealand; Haiti; Jamaica; Seychelles; Angola; Myanmar; Mexico; South Africa; India; Senegal; Congo; Mozambique; Colombia; Burundi; Japan; Taiwan; Fiji; Comoros
TSHR; NPSR1; | |
ACHE; | |
TDP1; PIK3CA; PIK3CB; ALOX12; HSD17B1; HSD17B10; NQO2; NOX4; POLB; | |
MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA9; CA14; CA4; CA7; | |
ESR2; ESR1; | |
KDM4E; | |
PTGS2; | |
MMP9; MMP2; MMP1; | |
NFKB1; | |
FUT7; | |
LMNA; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.171E-13 | 9.082E-09 | CA12, CA14, CA2, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.609E-10 | 1.524E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.461E-10 | 1.524E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.404E-09 | 2.352E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.257E-08 | 1.140E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.540E-08 | 1.341E-05 | CA12, CA2, CA4, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.503E-08 | 2.019E-05 | ALOX12, AURKB, AXL, CDK1, CSNK2A1, IGF1R, KDR, LMNA, MMP9, NFKB1, PIK3CA, PIM1, PTGS2 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 3.755E-08 | 2.720E-05 | ALOX12, CDK1, CSNK2A1, ESR1, FLT3, IGF1R, KDR, MMP2, MMP9, PIM1, PTGS2, THPO, TSHR |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 2.793E-07 | 1.267E-04 | ACHE, ALOX12, CSNK2A1, CYP19A1, CYP1A1, CYP3A4, HSD17B1, PIK3CA, PIK3CB, PTGS2 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.031E-06 | 3.917E-04 | AXL, MET, NOX4, PIK3CA, PIK3CB, THPO |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.148E-06 | 4.060E-04 | CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, MMP1, MMP2, MMP9, NQO2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.220E-06 | 4.126E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.391E-06 | 4.391E-04 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.675E-06 | 5.136E-04 | IGF1R, PIK3CA, PIK3CB |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 4.510E-06 | 1.212E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.841E-06 | 1.270E-03 | ESR1, ESR2 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.131E-05 | 2.507E-03 | CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4, PTGS2 |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.154E-05 | 2.507E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.197E-05 | 2.555E-03 | CA2, CA9, CSNK2A1, CYP1A2, ESR1, FLT3, NFKB1, PTGS2, TSHR |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.329E-05 | 2.783E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 2.924E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.450E-05 | 2.924E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.764E-05 | 3.492E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.962E-05 | 3.817E-03 | AXL, KDR, PIK3CA, PIK3CB |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.431E-05 | 4.374E-03 | AXL, CDK1, CSNK2A1, FLT3 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.578E-05 | 4.601E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.896E-05 | 4.851E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.896E-05 | 4.851E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.896E-05 | 4.851E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 3.238E-05 | 5.382E-03 | CYP19A1, CYP3A4, ESR1 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 3.781E-05 | 6.098E-03 | ACHE, HSD17B1, IGF1R, NQO2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 3.959E-05 | 6.339E-03 | CYP3A4, ESR1, ESR2, HSD17B1 |
BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 4.476E-05 | 6.912E-03 | AXL, NFKB1, NOX4, PIK3CA, PIK3CB, POLB, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.820E-05 | 7.340E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 5.612E-05 | 8.371E-03 | AXL, FLT3, IGF1R, KDR, MET |
CC | GO:0016020; membrane | GO:0005886; plasma membrane | 5.987E-05 | 8.809E-03 | ACHE, ALOX12, AXL, CA12, CA14, CA2, CA4, CA9, CSNK2A1, ESR1, FLT3, HSD17B10, IGF1R, KDR, MET, MMP2, NPSR1, PIK3CA, PIK3CB, PIM1, TDP1, TSHR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.347E-13 | 1.210E-10 | CA12, CA2, CA4, CA7, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.017E-09 | 7.374E-08 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 9.070E-09 | 3.043E-07 | PIK3CA, FLT3, MMP1, MMP2, PIK3CB, PTGS2, MET, MMP9, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.049E-08 | 3.043E-07 | PIK3CA, MMP2, KDR, PIK3CB, ESR1, MMP9, MET, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.558E-09 | 1.236E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.635E-08 | 1.603E-06 | PIK3CA, MMP2, PIK3CB, ESR1, MMP9, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.393E-07 | 2.885E-06 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.544E-07 | 8.236E-06 | PIK3CA, PIK3CB, ESR1, NFKB1, ESR2 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.457E-06 | 3.563E-05 | PIK3CA, MMP2, PIM1, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 3.025E-06 | 3.987E-05 | PIK3CA, PIM1, CYP1B1, PTGS2, MMP9, MET, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.722E-07 | 1.405E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 3.743E-06 | 4.522E-05 | PIK3CA, PIK3CB, PTGS2, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 8.589E-06 | 8.546E-05 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 6.271E-06 | 6.995E-05 | PIK3CA, PIK3CB, PTGS2, TSHR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 8.841E-06 | 8.546E-05 | PIK3CA, KDR, PIK3CB, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.621E-05 | 1.382E-04 | PIK3CA, PIK3CB, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.286E-05 | 1.166E-04 | PIK3CA, FLT3, PIK3CB, MET |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.960E-05 | 2.814E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.810E-05 | 1.458E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 3.460E-05 | 2.641E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 4.907E-05 | 3.234E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 5.777E-05 | 3.642E-04 | PIK3CA, CDK1, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 4.075E-05 | 2.814E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.419E-05 | 4.185E-04 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 7.048E-05 | 3.931E-04 | CSNK2A1, PIK3CA, CDK1, PIK3CB, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 7.048E-05 | 3.931E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 7.557E-05 | 4.058E-04 | POLB, PIK3CA, CDK1, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.016E-05 | 3.931E-04 | PIK3CA, PIK3CB, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 8.659E-05 | 4.185E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.296E-04 | 9.793E-04 | PIK3CA, LMNA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.055E-04 | 9.030E-04 | PIK3CA, CSNK2A1, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.696E-04 | 1.117E-03 | PIK3CA, PIK3CB, MMP9, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 1.190E-04 | 5.390E-04 | PIK3CA, MMP2, PIK3CB, MMP9 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 3.640E-04 | 1.363E-03 | PIK3CA, THPO, PIM1, PIK3CB |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.084E-03 | 3.276E-03 | FUT7, HSD17B1, CYP1A2, CYP1A1, ALOX12, PTGS2, CYP3A4, CYP19A1, HSD17B10 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 8.663E-04 | 2.731E-03 | PIK3CA, PIK3CB, NFKB1, TSHR |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.520E-04 | 1.363E-03 | PIK3CA, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.685E-04 | 1.363E-03 | PIK3CA, PIK3CB, IGF1R |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 5.184E-04 | 1.748E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 5.184E-04 | 1.748E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.854E-04 | 1.363E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 3.854E-04 | 1.363E-03 | PIK3CA, PIK3CB, MET |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.221E-03 | 3.542E-03 | PIK3CA, ALOX12, PIK3CB |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.685E-04 | 1.363E-03 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 8.652E-05 | 4.185E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.321E-05 | 4.360E-04 | MMP1, MMP2, MMP9 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.395E-04 | 1.778E-03 | CSNK2A1, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 1.050E-03 | 3.239E-03 | CSNK2A1, PTGS2, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.747E-03 | 4.495E-03 | ACHE, PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.295E-03 | 3.681E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 6.294E-04 | 2.028E-03 | PIK3CA, PIK3CB, MET |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.531E-03 | 4.110E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.449E-03 | 3.965E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.449E-03 | 3.965E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.658E-03 | 4.372E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.249E-03 | 5.260E-03 | POLB, PIK3CA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 2.478E-03 | 5.614E-03 | THPO, FLT3, KDR, MET |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.080E-03 | 5.113E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.080E-03 | 5.113E-03 | PIK3CA, PIK3CB, ESR1 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.182E-03 | 5.188E-03 | PIK3CA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.182E-03 | 5.188E-03 | PIK3CA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 2.396E-03 | 5.514E-03 | PIK3CA, PIK3CB, IGF1R |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 2.860E-03 | 6.323E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.921E-03 | 6.323E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 4.174E-03 | 8.609E-03 | PIK3CA, PIK3CB, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.921E-03 | 6.323E-03 | PIK3CA, PIK3CB, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3.513E-03 | 7.383E-03 | PIK3CA, PIK3CB, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 4.736E-03 | 9.502E-03 | PIK3CA, PIK3CB, PTGS2 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 4.784E-03 | 9.502E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 4.215E-03 | 8.609E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.181E-03 | 6.783E-03 | PIK3CA, PIK3CB |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.767E-03 | 4.495E-03 | CYP1A2, CYP3A4 |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.110E-03 | 3.285E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; MMP2; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; PTGS2; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
NA: NA | GIST | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CYP19A1; CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; MMP1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; MMP9; PIK3CB; MMP2; CA9; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; CSNK2A1; NFKB1; FLT3; ACHE; MMP9; PTGS2; PIK3CB; NQO2; MMP2; CA9; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
NA: NA | Menopausal disorder | NA | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; MMP1; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |